Waldencast plc, through its subsidiary Obagi Medical, has announced a strategic collaboration with Moxie as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Moxie, recognized for its expertise in providing software, marketing, coaching, and compliance solutions to aesthetic practices, will support the real-world evaluation of Obagi® saypha® MagIQ™ across its network. The partnership aims to generate meaningful real-world evidence on the injectable's integration into med spa workflows, focusing on both clinical performance and patient experience. Initial results from this collaboration will be shared at upcoming industry events and conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649355-en) on February 05, 2026, and is solely responsible for the information contained therein.